|
Mar 8
|
Amylyx’s ALS Drug Fails Trial, Raising Questions About Company’s Future
|
|
Mar 8
|
10 Biotech Stocks with Huge Potential
|
|
Mar 8
|
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
|
|
Mar 8
|
Amylyx ALS drug fails crucial study, putting company’s future in doubt
|
|
Jan 5
|
2 Biotech Stocks With Huge Catalysts in 2024
|
|
Dec 26
|
Is Amylyx (AMLX) Stock a Solid Choice Right Now?
|
|
Dec 22
|
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
|
|
Dec 4
|
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
|
|
Nov 29
|
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 28
|
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
|
|
Nov 27
|
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
|
|
Nov 12
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript
|
|
Nov 10
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock's 34% Dive Might Signal An Opportunity But It Requires Some Scrutiny
|
|
Nov 10
|
Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call
|
|
Nov 9
|
Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024
|
|
Nov 9
|
Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth
|
|
Nov 9
|
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
|
|
Nov 4
|
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
|
|
Nov 2
|
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
|
|
Nov 2
|
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
|